Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and remains an important public health concern because its incidence has continued to increase globally [2] . Many different kinds of approaches, such as surgical resection, liver transplantation, radiofrequency ablation (RFA), transarterial chemoembolization (TACE), chemotherapy, and sorafenib, are performed according to practical guidelines for the treatment of HCC [3] ; however, their effects are limited and the recurrence rate of HCC remains very high [4] . Moreover, patients who have already developed HCC are mostly in an advanced stage at the time of diagnosis and, as such, the efficacy of surgical resection, RFA, and TACE is limited for such cases. Although sorafenib has been shown to have a significant survival benefit in several large-scale clinical trials and has been established as the standard treatment for advanced HCC [5] , its efficacy and tolerability are also limited [6] . Hepatic arterial infusion chemotherapy (HAIC) has been employed as an alternative therapy to sorafenib in Japan and other Asian countries [7, 8] .
The modulation of tumor-associated host immune responses after cancer treatments has recently been reported. For example, HCC treatments with RFA or TACE were found to increase the frequency of tumorassociated antigen (TAA)-specific T cells due to the creation of an antigen source by the destruction of tumor cells [9, 10] . In addition, recent studies demonstrated that beyond their direct cytotoxic effects on cancer cells, several conventional chemotherapeutic drugs promoted the elimination or inactivation of regulatory T cells (Tregs) or myeloid-derived suppressor cells (MDSCs), resulting in enhanced host antitumor immunity [11, 12] . These findings support the immunotherapeutic effects of HAIC for HCC. However, the effects of HAIC on host immune responses and the relationship between the prognosis of patients treated with HAIC and host immune responses remain unclear.
In the present study, we performed a comparative analysis of various immune cell responses including TAA-specific T cells, Tregs, and MDSCs in advanced HCC patients treated with HAIC.
Materials and methods

Patients and laboratory testing
Thirty-six human histocompatibility leukocyte antigen (HLA)-A24-positive patients who had clinically diagnosed HCC were examined in the present study (Table 1) . HCC All of the patients in this study were first-line patients. In the IFN/FU treatment group, patients received a continuous hepatic arterial infusion of FU (5-FU, Kyowa Hakko, Tokyo, Japan) at a dose of 300 mg/m 2 /day for 5 days in the 1st and 2nd weeks (for 120 h) using an infuser pump (Baxter Infusor SV1, Tokyo, Japan) as described previously [13] . The maximum amount of FU infused over 5 days was 2,500 mg. IFN α-2b (Intron A, Schering-Plough, Osaka, Japan) at a dose of 3,000,000 units was injected intramuscularly 3 times a week for 4 weeks. In the IFN/FU + cisplatin treatment group, cisplatin (Randa, Nippon Kayaku, Tokyo, Japan) at a dose of 20 mg/m 2 was given by a hepatic arterial infusion over 1.5 h on days 1 and 8 prior to the administration of FU and after appropriate hydration and antiemetic medication. A treatment cycle comprised 4 weeks of drug administration including the administration of IFN and a subsequent 2-week rest period.
The response rate after HAIC was determined using dynamic computed tomography or magnetic resonance imaging performed at the end of each treatment cycle according to the Response Evaluation Criteria in Solid Tumors, version 1.1 [14] . The overall survival time was defined as the period from the time of beginning of treatment until death, and the progression-free survival time was defined as the period from the beginning of the treatment until the confirmation of progression or death.
Blood samples were tested for hepatitis B virus surface antigen (HBsAg) and hepatitis C virus antibody (HCVAb) using commercial immunoassays (Fuji Rebio, Tokyo, Japan). The HLA-based typing of peripheral blood mononuclear cells (PBMCs) from patients and normal blood donors was performed as described previously [15] . Serum alpha-fetoprotein (AFP) levels were measured by an enzyme immunoassay (AxSYM AFP, Abbott Japan, Tokyo, Japan).
All patients provided written informed consent to participate in the study in accordance with the Helsinki Declaration and this study was approved by the regional Ethics Committee (Medical Ethics Committee of Kanazawa University, No. 5169).
Peptides and preparation of PBMCs
Eleven peptides derived from 5 different TAAs (Supplementary Table 1 ) [10] , a human immunodeficiency virus (HIV) envelope-derived peptide (HIVenv 584 ) [16] , and cytomegalovirus (CMV) pp65-derived peptide (CMVpp65 328 ) [17] , which were previously identified as HLA-A24-restricted cytotoxic T lymphocyte (CTL) epitopes were used. Peptides were synthesized at Sumitomo Pharmaceuticals (Osaka, Japan). They were identified using mass spectrometry, and their purities were determined to be >90 % by analytical high-performance liquid chromatography (HPLC). PBMCs were isolated before and 2-4 weeks after starting HAIC as described below; heparinized venous blood was diluted in phosphatebuffered saline (PBS) and loaded on Ficoll-Histopaque (Sigma, St. Louis, Mo.) in 50-ml tubes. After centrifugation at 2000 rpm for 20 min at room temperature, PBMCs were harvested from interphase, resuspended in PBS, centrifuged at 1400 rpm for 10 min, and then resuspended in complete culture medium consisting of Roswell Park Memorial Institute (RPMI) culture medium (GibcoBRL, Grand Island, NY), 10 % heat inactivated fetal calf serum (FCS) (Gibco BRL), 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco BRL). PBMCs were resuspended in RPMI 1640 medium containing 80 % FCS and 10 % dimethyl sulfoxide, and cryopreserved until use.
IFN-γ ELISPOT assay
IFN-γ enzyme-linked immunospot (ELISPOT) assays were performed as reported previously [18] . Negative controls consisted of a HIV envelope-derived peptide (HIVenv 584 ) [16] . Positive controls consisted of 10 ng/ ml phorbol 12-myristate 13-acetate (PMA, Sigma) or a CMV pp65-derived peptide (CMVpp65 328 ) [17] . The amino acid sequences of all peptides are shown in Supplementary Table 1 . The colored spots were counted with a KS ELISpot Reader (Zeiss, Tokyo, Japan). The number of specific spots was determined by subtracting the number of spots in the absence of an antigen from the number in its presence. Responses to TAA-derived peptides were considered positive if more than 10 specific spots were detected, which is greater than the mean plus 3 standard deviation of the baseline response detected in 11 normal blood donors (Supplementary Table 1) , and if the number of spots in the presence of an antigen was at least twofold that in its absence. Responses to HIV-and CMV-derived peptides were considered positive if more than ten specific spots were detected and if the number of spots in the presence of an antigen was at least twofold that in its absence.
Flow cytometric analysis
A multicolor fluorescence-activated cell sorting analysis was carried out using the Becton-Dickinson FACSAria II system to determine the frequency and phenotype of Tregs and MDSCs. The following anti-human monoclonal antibodies were used: anti-cluster of differentiation
, antiprogrammed death ligand 1 (PD-L1) (BioLegend) and anti-HLA-DR (Becton-Dickinson).
Cytokine profiling
Cytokine levels in serum were measured using the Procarta ® Cytokine Assay (Affymetrix, Santa Clara, CA) as previously reported [19] . These included interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10 and transforming growth factor (TGF)-β1. Data acquisition and analysis were carried out using Bio-plex Manager software version 4.1.1.
Statistical analysis
Data are expressed as mean ± standard deviation. The Chi-squared test with Yates' correction, paired t test, and unpaired t test were used for statistical analyses where appropriate. The probabilities of overall survival were estimated using the Kaplan-Meier method. The Mantel-Cox log-rank test was used to compare curves between groups. The prognostic factors for overall survival were analyzed for significance by the Kaplan-Meier method (univariate). A level of p < 0.05 was considered significant.
Results
Patient profiles
The clinical profiles of the 36 patients with advanced HCC who participated in the present study are shown in Table 1 . Major portal vein invasion, lymph node metastasis, and distant metastasis were noted in 15, 1, and 3 patients, respectively. Using Barcelona clinic liver cancer (BCLC) TNM staging, 19, 15, and 2 patients were classified as stage B, C, and D, respectively. Using TNM staging of the Union Internationale Contre Le Cancer (UICC) system (6th version), 4, 29, and 3 patients were classified as stage II, III and IV, respectively. Thirty patients had liver cirrhosis and 16, 18, and 2 patients were classified as grade A, B, and C according to the Child-Pugh classification. Among the 36 patients, the best study response was a complete response (CR) in 1 (2.8 %) patient; a partial response (PR) was observed in 18 (50.0 %) patients, stable disease (SD) was observed in 6 (16.7 %) patients, and progressive disease (PD) was observed in 11 (30.6 %) patients.
Detection of TAA-specific T cells
The detection of TAA-specific T cells was performed by a direct ex vivo analysis (IFN-γ ELISPOT assay). The cut-off of positivity was set at ≥10 specific spots/300,000 PBMCs (see "Materials and methods"). We examined the frequency of cells that specifically reacted with TAA-derived and control peptides using PBMCs obtained before the treatment with HAIC. Nineteen responses were observed against TAA-derived peptides. Eleven out of 36 (30.6 %) patients showed positive responses to at least one TAA-derived peptide, while most showed responses to 1-3 kinds of TAAderived peptide. The magnitude of TAA-specific T cell responses was assessed by the frequency of peptide-specific IFN-γ-producing T cells in the PBMC population. The range of the TAA-derived peptide-specific T cell frequency was 10.0-67.0 cells/300,000 PBMCs. The frequencies of T cells specific to CMV-derived peptides were 10.0-299.5 cells/300,000 PBMCs, respectively.
We performed the same analysis using PBMCs obtained 2-4 weeks after starting HAIC. When T cell responses against a single peptide with more than or equal to 10 specific spots and a twofold increase were defined as significant, the number of patients who showed a significant increase against at least one TAA-derived peptide after HAIC was 8 (22.2 %). However, no significant differences were observed in the frequency of patients who specifically reacted with TAA-derived and control peptides after the treatment (Supplementary Table 1 ).
Detection of Tregs and MDSCs
We examined the frequency of Tregs and MDSCs in peripheral blood in order to identify the effects of HAIC on immune suppressor cells. The population of Tregs was detected as CD4 + CD25 + CD127 −/low cells as previously reported (Fig. 1a) [20] . We also confirmed that this population was highly positive for CD25 and FOXp3. The frequency of Tregs varied greatly (1.9-12.1 %) in HCC patients before HAIC and was significantly decreased after the treatment (p = 0.043) (Fig. 1b) 
HLA-DR
−/low detected in this study showed 2 cell populations with low and high PD-L1 expression. After HAIC treatment, the expression levels of PD-L1 in CD14 +
− MDSCs were increased in most of the patients examined ( Supplementary Fig. 1b and c) . The CD14 +
−/low population in the PBMCs of HCC patients represented 10.5 to 71.3 % of CD14 + cells before HAIC. In contrast to Tregs, no significant differences were observed in the frequency of MDSCs after HAIC (p = 0.609) (Fig. 1d) . We observed a decrease in serum TGF-β1 concentration after HAIC ( Supplementary  Fig. 1a ). The concentrations of other cytokines did not change with statistical significance before and after the treatment.
Identification of host factors related to the frequencies of Tregs and MDSCs
To identify host factors related to the frequencies of Tregs and MDSCs, we compared the frequencies of these immune suppressor cells with various clinical factors. Although the (Fig. 2a) .
In contrast to Tregs, the frequency of MDSCs was associated with these tumor factors. Patients with the advanced UICC stage, a large tumor diameter, major portal vein invasion, and distant metastasis of HCC showed a high frequency of MDSCs in peripheral blood (Fig. 2b) . Patients with a high neutrophil to lymphocyte ratio (NLR), which has been suggested to be associated with the outcomes of patients with various malignancies [22, 23] , also showed a high frequency of MDSCs.
Patient outcomes and frequencies of Tregs and MDSCs
We examined the relationship between patient outcomes and the frequencies of Tregs and MDSCs. Patients were divided into two groups: patients with CR or PR and those with SD or PD, and the frequencies of Tregs and MDSCs were compared between these groups before and after the treatment. No significant differences were observed in the frequency of Tregs between these groups before and after the treatment ( Fig. 3a, b) . In contrast, the frequency of MDSCs was significantly lower in the group with CR or PR before the treatment than in the group with SD or PD (p = 0.006) (Fig. 3c) . Similar results were also obtained in the analysis of MDSCs after the treatment (p = 0.043) (Fig. 3d) .
Effects of immune cells on the prognosis of patients treated with HAIC
To determine the effects of various immune cells on the prognosis of HCC patients treated with HAIC, we analyzed the relationship between the frequencies of immune cells, consisting of TAA-specific T cells, Tregs, and MDSCs, before the treatment and overall survival after HAIC. To analyze TAA-specific T cells, we divided patients into two groups: those with high (above median) and low (below median) specific spots as detected by the ELISPOT assay. We did not find any associations between the frequency of TAA-specific T cells, which was calculated as a total number of T cells detected by IFN-γ ELISPOT assay using 11 TAA-derived peptides (Supplementary Table 1) , and overall survival after HAIC (Fig. 4a) . The frequency of Tregs before the treatment was also not associated with the overall survival of patients treated with HAIC (Fig. 4b ). In contrast, the overall survival of patients with a high frequency of MDSCs before the treatment was significantly shortened (p = 0.003) (Fig. 4c) . The difference between the groups was emphasized when 40 % was defined as high (p < 0.001) (Fig. 4d) .
A univariate analysis of prognostic factors for overall survival identified NLR (<2.1), diameter of the tumor (<3.0 cm), absence of major portal vein invasion, absence of distant metastasis, BCLC TNM stage (A or B), UICC TNM stage (I or II), and the frequency of MDSCs (<30.5 %) as factors that prolonged the overall survival time after HAIC (Table 2 ). Since the number of patients was insufficient for a multivariate analysis of prognostic factors for overall survival and the frequency of MDSCs was associated with the progression of tumors, as shown in Fig. 4e , we examined the relationship between the frequency of MDSCs and overall survival after HAIC in a limited patient group with only UICC TNM stage II or III. Even in the group adjusted with progressive levels of tumors, patients with a low frequency of MDSCs had a significantly longer overall survival time (p = 0.010) (Fig. 4e) .
Discussion
Increases have been reported in the frequency of TAAspecific T cells after treatments for HCC such as RFA and TACE [9, 10] . In the present study, we found an increase in the frequency of TAA-specific T cells after HAIC in a very limited number of patients, which was unexpected. The 36 patients evaluated in this study included 19 who showed CR or PR to the treatment and decreases in the tumor size. However, an analysis of changes in the frequency of T cells specific to each epitope revealed increases in only 4 out of This result suggested that HAIC using cisplatin and 5FU induced necrosis or apoptosis in tumor tissue, but was not appropriate for inducing anti-tumor immunity, unlike RFA and TACE. Recent studies reported that anti-tumor chemotherapy produced its anti-tumor effects by not only direct cytotoxic effects against tumor cells, but also the elimination or inactivation of cells with suppressive effects on tumor immunity such as Tregs and MDSCs [11, 12] . In the present study, the frequency of Tregs also decreased after the treatment, which was consistent with the previously reported responses of Tregs to chemotherapy against colon cancer using cyclophosphamide and non-small cell lung cancer using paclitaxel [24, 25] . The decrease was more prominent in patients with the higher frequency of Tregs pretreatment, suggesting the treatment might be more effective in such patients. However, the decrease observed in the number of Tregs did not appear to contribute to the increase in the frequency of TAA-specific T cells.
No significant changes were observed in the frequency of MDSCs after the treatment. The chemotherapy evaluated in this study included 5FU, which has been reported to reduce the frequency of MDSCs in peripheral blood in mouse thymoma and colorectal cancer models and humans with colorectal cancer [26, 27] . Similar results were not obtained in the present study using 5FU presumably because of the difference in its administration route, which was via the hepatic artery. Previous studies on the pharmacokinetics of 5FU reported that the concentration of 5FU in peripheral blood was lower by an administration route via the hepatic artery than by an intravenous administration route [28] , and this is considered to have been a reason for the failure in this study to reduce the frequency of MDSCs. There was no statistically significant difference between the patients treated with IFN/5FU and IFN/5FU + cisplatin regarding the clinical data and the frequency of TAAspecific T cells, Tregs and MDSCs before and after the treatment.
We previously reported that the frequency of MDSCs decreased after RFA, a standard treatment for HCC, and also that the number of TAA-specific T cells after this treatment negatively correlated with the frequency of MDSCs [10] . In this study, in 8 patients showing increased TAAspecific T cell responses to at least one TAA-derived peptide after HAIC, 3 and 2 patients showed a decreasing of number of Tregs and MDSCs, respectively. Although the absence of an increase in the number of TAA-specific T cells after chemotherapy in the present study might be related to a failure in the induction of a decrease in the frequency of MDSCs by the treatment, the relationship should be further studied. In addition, one of the limitations of this study is that the function of Tregs and MDSCs has not been investigated. It also should be further studied. An analysis of the relationships between TAA-specific T cells, Tregs, and MDSCs and the therapeutic effects observed revealed that the frequency of MDSCs before the treatment was significantly lower in the patients that showed CR or PR to HAIC than in those showed SD or PD. No significant difference was observed in the frequency of TAA-specific T cells or Tregs before the treatment and the frequency of these 2 kinds of cells after the beginning of the treatment. Furthermore, an analysis of patient outcomes after the treatment showed a longer overall survival period in patients with a lower frequency of MDSCs before the treatment. These results were consistent with previous findings in many cancer types [29] and suggested that the frequency of MDSCs is an important prognostic factor in HCC patients undergoing HAIC.
Regarding host factors that affect the frequency of MDSCs, the degree of tumor progression indicated by the UICC stage, BCLC stage, diameter of the tumor, major portal vein invasion, and distant metastasis correlated with a high frequency of MDSCs, i.e., the frequency of MDSCs increased in patients with more advanced disease. Furthermore, a univariate analysis of factors contributing to overall survival identified a low frequency of MDSCs, low UICC or BCLC stage, tumors with small diameters, and the absence of major portal vein invasion and distant metastasis as significant factors. Since a multivariate analysis was not performed in this study due to the lack of a sufficient number of patients, it currently remains unknown whether the frequency of MDSCs influenced patient outcomes directly via immunological mechanisms or indirectly by reflecting the degree of tumor progression. Therefore, in order to elucidate the relationship between the frequency of MDSCs and patient outcomes in greater detail, we examined the relationship between the frequency of MDSCs and overall survival in UICC stage II or III patients. In this analysis, the overall survival was significantly longer in the group with a lower frequency of MDSCs even with standardization of the disease stage, suggesting that the frequency of MDSCs was an independent factor contributing to overall survival. Moreover, we recently reported a higher recurrence-free survival rate and longer overall survival in patients with a low NLR before the treatment and suggested that the NLR was a prognostic factor in HAIC [30] . The frequency of MDSCs was lower in patients with a low NLR, suggesting that they are related. A review of the literature revealed that the relationship between MDSCs and the NLR has not yet been directly demonstrated, the NLR in HCC has been shown to reflect systemic or intratumoral micro-environmental inflammatory responses and correlated with intratumoral or systemic IL-17 concentrations [31] . Since MDSCs are induced by systemic inflammatory responses and are related to Th17 cell differentiation [32] , an increase in the NLR has been suggested to be caused by an increase in MDSCs or the cytokines produced by them. These results also indicate that MDSCs are related to patient outcomes by some immunological mechanism.
In conclusion, this study showed that the frequency of MDSCs before the treatment was a prognostic factor in HAIC against HCC. The results of this study, which suggest that the frequency of MDSCs is a good clinical marker for the selection of patients treated with HAIC and the effectiveness of HAIC could be enhanced by controlling the frequency of MDSCs before the treatment, provide a useful insight into devising therapeutic strategies against HCC. The patients with high frequency of MDSCs before treatment might be better treated with another chemotherapeutic agent or sorafenib. 
